CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-14 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −2,118 | $59.52 | $126K | 1,291,976 |
| 2026-10-14 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −382 | $60.14 | $23K | 1,291,594 |
| 2026-10-09 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +192 | $39.42 | $8K | 105,464 |
| 2026-10-09 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −192 | $64.26 | $12K | 105,272 |
| 2026-10-09 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −192 | 2,267 | ||
| 2026-10-07 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −2,447 | $63.38 | $155K | 1,294,147 |
| 2026-10-07 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −53 | $63.95 | $3K | 1,294,094 |
| 2026-10-06 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +435 | $39.42 | $17K | 105,707 |
| 2026-10-06 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −435 | $64.16 | $28K | 105,272 |
| 2026-10-06 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −435 | 2,459 | ||
| 2026-10-05 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +1,638 | $39.42 | $65K | 106,910 |
| 2026-10-05 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,638 | $64.03 | $105K | 105,272 |
| 2026-10-05 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,638 | 2,894 | ||
| 2026-09-30 | STEELE GLENN JR MD PHD Director | Option exercise 10b5-1 | +12,000 | $11.23 | $135K | 34,500 |
| 2026-09-30 | STEELE GLENN JR MD PHD Director | Sale 10b5-1 | −12,000 | $65.16 | $782K | 22,500 |
| 2026-09-30 | STEELE GLENN JR MD PHD Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 0 | ||
| 2026-09-17 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −9,624 | $67.83 | $653K | 1,296,970 |
| 2026-09-17 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −376 | $68.45 | $26K | 1,296,594 |
| 2026-09-16 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −2,994 | $66.58 | $199K | 1,313,600 |
| 2026-09-16 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 | −7,006 | $67.35 | $472K | 1,306,594 |
Page 1 of 25 · 493 trades